Publishing research using ab27766? Please let us know so that we can cite the reference in this datasheet.

ab27766 has been referenced in 25 publications.

  • Gerson JE  et al. Tau oligomers mediate a-synuclein toxicity and can be targeted by immunotherapy. Mol Neurodegener 13:13 (2018). PubMed: 29544548
  • Finkelstein DI  et al. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. Acta Neuropathol Commun 5:53 (2017). WB ; Human . PubMed: 28659169
  • Stolzenberg E  et al. A Role for Neuronal Alpha-Synuclein in Gastrointestinal Immunity. J Innate Immun 9:456-463 (2017). PubMed: 28651250
  • Evsyukov V  et al. Genetic mutations linked to Parkinson's disease differentially control nucleolar activity in pre-symptomatic mouse models. Dis Model Mech 10:633-643 (2017). PubMed: 28360124
  • Chai YJ  et al. Munc18-1 is a molecular chaperone for a-synuclein, controlling its self-replicating aggregation. J Cell Biol 214:705-18 (2016). PubMed: 27597756
  • Ma MR  et al. Phosphorylation induces distinct alpha-synuclein strain formation. Sci Rep 6:37130 (2016). WB ; Mouse . PubMed: 27853185
  • Brahmachari S  et al. Activation of tyrosine kinase c-Abl contributes to a-synuclein-induced neurodegeneration. J Clin Invest 126:2970-88 (2016). PubMed: 27348587
  • Zha J  et al. A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses. Sci Rep 6:36631 (2016). WB . PubMed: 27824125
  • Tousseyn T  et al. Prion Disease Induces Alzheimer Disease-Like Neuropathologic Changes. J Neuropathol Exp Neurol 74:873-88 (2015). PubMed: 26226132
  • Iacono D  et al. Reduced Number of Pigmented Neurons in the Substantia Nigra of Dystonia Patients? Findings from Extensive Neuropathologic, Immunohistochemistry, and Quantitative Analyses. Tremor Other Hyperkinet Mov (N Y) 5:N/A (2015). IHC-P ; Human . PubMed: 26069855
  • Flores-Cuadrado A  et al. a-Synuclein staging in the amygdala of a Parkinson's disease model: cell types involved. Eur J Neurosci 41:137-46 (2015). IHC . PubMed: 25345880
  • Bétemps D  et al. Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological a-synuclein by enhanced ELISA. Acta Neuropathol Commun 2:29 (2014). WB, ELISA . PubMed: 24624994
  • Buehl CJ  et al. Resolving acetylated and phosphorylated proteins by neutral urea Triton-polyacrylamide gel electrophoresis: NUT-PAGE. Biotechniques 57:72-80 (2014). PubMed: 25109292
  • Arawaka S  et al. Zonisamide attenuates a-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease. PLoS One 9:e89076 (2014). WB . PubMed: 24586512
  • Rockenstein E  et al. Accumulation of oligomer-prone a-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain 137:1496-513 (2014). WB ; Human . PubMed: 24662516
  • Hall H  et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. Brain 137:2493-508 (2014). Human . PubMed: 25062696
  • Acosta SA  et al. Alpha-synuclein as a Pathological Link between Chronic Traumatic Brain Injury and Parkinson's disease. J Cell Physiol N/A:N/A (2014). PubMed: 25251017
  • Boassa D  et al. Mapping the subcellular distribution of a-synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson's disease pathogenesis. J Neurosci 33:2605-15 (2013). Human . PubMed: 23392688
  • Kim MO  et al. Genetic CJD with a novel E200G mutation in the prion protein gene and comparison with E200K mutation cases. Acta Neuropathol Commun 1:80 (2013). IHC ; Human . PubMed: 24330864
  • Henderson-Smith A  et al. SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening. PLoS One 8:e77711 (2013). WB . PubMed: 24204929
  • Cannon JR  et al. Expression of human E46K-mutated a-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment. Exp Neurol 240:44-56 (2013). PubMed: 23153578
  • Talbot K  et al. Synaptic dysbindin-1 reductions in schizophrenia occur in an isoform-specific manner indicating their subsynaptic location. PLoS One 6:e16886 (2011). IHC-P ; Human . PubMed: 21390302
  • Scott DA  et al. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci 30:8083-95 (2010). PubMed: 20554859
  • Jakes R  et al. Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. Neurosci Lett 269:13-6 (1999). PubMed: 10821633
  • Giasson BI  et al. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 274:7619-22 (1999). PubMed: 10075647


Sign up